<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. MRNA, -3.84% gained 0.9% in premarket trading on Monday after the company shared interim data from a Phase 2/3 clinical study evaluating its COVID-19 vaccine in children between the ages of 6 and 11 years old. The trial, which has 4,753 participants between the ages of 6 and 11, evaluated the immune response one month after the second dose.
...read full article on Market Watch
